In addition, the new molecules used in the treatment of T2D, such as sodium–glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-like peptide 1 receptor (GLP-1) agonists, also have an effect on body composition that should be considered at the time of treatment initiation, especially in older adults [69]. Here, GLP1R is linked to type 2 diabetes mellitus.